Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE eltrombopag study in thrombocytopenic MDS or AML
NL-OMON39136Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in Thrombocytopenia (4 arms), sponsored by GSK. Primary endpoints: Composite clinically relevant thrombocytopenic events, Safety and tolerability and 2 more. Started Apr 2013; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NL-OMON39136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39136.